SE503225C2 - Virus-antikroppskomplex för införing av virus i mammalieceller - Google Patents

Virus-antikroppskomplex för införing av virus i mammalieceller

Info

Publication number: SE503225C2
Authority: SE; Sweden
Prior art keywords: antibody; virus; viral; complex according; complex
Prior art date: 1991-10-30

Application number

SE9103183A

Other languages

English (en)

Swedish (sv)

Other versions

SE9103183D0 (sv

SE9103183L (sv

Inventor

Leif Lindholm

Sven Enerbaeck

Oerjan Strannegaard

Original Assignee

Leif Lindholm Konsult Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-30

Filing date

1991-10-30

Publication date

1996-04-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20384166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE503225(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-10-30 Application filed by Leif Lindholm Konsult Ab filed Critical Leif Lindholm Konsult Ab

1991-10-30 Priority to SE9103183A priority Critical patent/SE503225C2/sv

1991-10-30 Publication of SE9103183D0 publication Critical patent/SE9103183D0/xx

1992-10-28 Priority to EP92922980A priority patent/EP0614486B1/de

1992-10-28 Priority to US08/232,028 priority patent/US5695991A/en

1992-10-28 Priority to DE69232782T priority patent/DE69232782T2/de

1992-10-28 Priority to CA002122613A priority patent/CA2122613C/en

1992-10-28 Priority to PCT/SE1992/000745 priority patent/WO1993009221A1/en

1992-10-28 Priority to ES92922980T priority patent/ES2180538T3/es

1992-10-28 Priority to AT92922980T priority patent/ATE224442T1/de

1992-10-28 Priority to JP5508351A priority patent/JPH07502026A/ja

1993-05-01 Publication of SE9103183L publication Critical patent/SE9103183L/

1996-04-22 Publication of SE503225C2 publication Critical patent/SE503225C2/sv

Links

241000700605 Viruses Species 0.000 title claims abstract description 40
210000004962 mammalian cell Anatomy 0.000 title claims abstract description 9
210000004027 cell Anatomy 0.000 claims abstract description 46
239000000427 antigen Substances 0.000 claims abstract description 19
102000036639 antigens Human genes 0.000 claims abstract description 18
108091007433 antigens Proteins 0.000 claims abstract description 18
230000027455 binding Effects 0.000 claims abstract description 17
208000015181 infectious disease Diseases 0.000 claims abstract description 7
239000013598 vector Substances 0.000 claims abstract description 7
230000002458 infectious effect Effects 0.000 claims abstract description 4
108090000623 proteins and genes Proteins 0.000 claims description 29
230000003612 virological effect Effects 0.000 claims description 16
102000004169 proteins and genes Human genes 0.000 claims description 12
230000001413 cellular effect Effects 0.000 claims description 8
239000003446 ligand Substances 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 5
239000003153 chemical reaction reagent Substances 0.000 claims description 4
238000010353 genetic engineering Methods 0.000 claims description 4
210000000170 cell membrane Anatomy 0.000 claims description 3
239000012634 fragment Substances 0.000 claims description 3
210000000056 organ Anatomy 0.000 claims description 3
230000035515 penetration Effects 0.000 claims description 3
239000013603 viral vector Substances 0.000 claims description 3
230000001588 bifunctional effect Effects 0.000 claims description 2
238000010367 cloning Methods 0.000 claims description 2
238000001179 sorption measurement Methods 0.000 claims 5
108010032595 Antibody Binding Sites Proteins 0.000 claims 2
108091028043 Nucleic acid sequence Proteins 0.000 claims 2
210000003462 vein Anatomy 0.000 claims 2
108090001008 Avidin Proteins 0.000 claims 1
108010090804 Streptavidin Proteins 0.000 claims 1
230000000149 penetrating effect Effects 0.000 claims 1
210000003850 cellular structure Anatomy 0.000 abstract 1
101710154606 Hemagglutinin Proteins 0.000 description 6
101710093908 Outer capsid protein VP4 Proteins 0.000 description 6
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 6
101710176177 Protein A56 Proteins 0.000 description 6
108070000030 Viral receptors Proteins 0.000 description 6
239000000185 hemagglutinin Substances 0.000 description 6
230000035931 haemagglutination Effects 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
102000007238 Transferrin Receptors Human genes 0.000 description 3
108010033576 Transferrin Receptors Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
229940127121 immunoconjugate Drugs 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
208000037797 influenza A Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000004779 membrane envelope Anatomy 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
241000712461 unidentified influenza virus Species 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
WDVIDPRACNGFPP-QWRGUYRKSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WDVIDPRACNGFPP-QWRGUYRKSA-N 0.000 description 1
RSRKICWWOYBARZ-UHFFFAOYSA-N (pyridin-2-yldisulfanyl) propanoate Chemical compound CCC(=O)OSSC1=CC=CC=N1 RSRKICWWOYBARZ-UHFFFAOYSA-N 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102100032768 Complement receptor type 2 Human genes 0.000 description 1
101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241001500351 Influenzavirus A Species 0.000 description 1
101100293261 Mus musculus Naa15 gene Proteins 0.000 description 1
-1 N-succinimidyl (2-pyridyldithio) Chemical class 0.000 description 1
101150082943 NAT1 gene Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
102100023105 Sialin Human genes 0.000 description 1
101710105284 Sialin Proteins 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000003889 chemical engineering Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000003067 hemagglutinative effect Effects 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000006177 thiolation reaction Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Plant Pathology (AREA)
Virology (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
Pulmonology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SE9103183A 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller SE503225C2 (sv)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
SE9103183A SE503225C2 (sv)	1991-10-30	1991-10-30	Virus-antikroppskomplex för införing av virus i mammalieceller
JP5508351A JPH07502026A (ja)	1991-10-30	1992-10-28	ウイルス抗体複合体
AT92922980T ATE224442T1 (de)	1991-10-30	1992-10-28	Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.
DE69232782T DE69232782T2 (de)	1991-10-30	1992-10-28	Zielgerichtetes Einbringen eines Virus-Vektors in Säugetierzellen.
US08/232,028 US5695991A (en)	1991-10-30	1992-10-28	Targeted delivery of virus vector to mammalian cells
EP92922980A EP0614486B1 (de)	1991-10-30	1992-10-28	Zielgerichtetes Einbringen eines Virus-Vektors in Säugetierzellen.
CA002122613A CA2122613C (en)	1991-10-30	1992-10-28	Targeted delivery of virus vector to mammalian cells
PCT/SE1992/000745 WO1993009221A1 (en)	1991-10-30	1992-10-28	Targeted delivery of virus vector to mammalian cells
ES92922980T ES2180538T3 (es)	1991-10-30	1992-10-28	Suministro dirigido de vector virico a celulas de mamiferos.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9103183A SE503225C2 (sv)	1991-10-30	1991-10-30	Virus-antikroppskomplex för införing av virus i mammalieceller

Publications (3)

Publication Number	Publication Date
SE9103183D0 SE9103183D0 (sv)	1991-10-30
SE9103183L SE9103183L (sv)	1993-05-01
SE503225C2 true SE503225C2 (sv)	1996-04-22

Family

ID=20384166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9103183A SE503225C2 (sv)	1991-10-30	1991-10-30	Virus-antikroppskomplex för införing av virus i mammalieceller

Country Status (9)

Country	Link
US (1)	US5695991A (de)
EP (1)	EP0614486B1 (de)
JP (1)	JPH07502026A (de)
AT (1)	ATE224442T1 (de)
CA (1)	CA2122613C (de)
DE (1)	DE69232782T2 (de)
ES (1)	ES2180538T3 (de)
SE (1)	SE503225C2 (de)
WO (1)	WO1993009221A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7820157B2 (en)	1997-04-10	2010-10-26	University Of Southern California	Transgene delivering retrovirus targeting collagen exposed at site of tissue injury

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE503225C2 (sv) *	1991-10-30	1996-04-22	Leif Lindholm Konsult Ab	Virus-antikroppskomplex för införing av virus i mammalieceller
GB9223084D0 (en) *	1992-11-04	1992-12-16	Imp Cancer Res Tech	Compounds to target cells
DE4311651A1 (de) *	1993-04-08	1994-10-13	Boehringer Ingelheim Int	Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US6465253B1 (en)	1994-09-08	2002-10-15	Genvec, Inc.	Vectors and methods for gene transfer to cells
US5846782A (en)	1995-11-28	1998-12-08	Genvec, Inc.	Targeting adenovirus with use of constrained peptide motifs
US5753499A (en) *	1994-12-23	1998-05-19	New York University	Viral vector complexes having adapters of predefined valence
US5770442A (en)	1995-02-21	1998-06-23	Cornell Research Foundation, Inc.	Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) *	1995-02-21	2000-10-03	Cornell Research Foundation, Inc.	Chimeric adenoviral coat protein and methods of using same
US6261554B1 (en)	1995-07-25	2001-07-17	Introgene B.V.	Compositions for targeted gene delivery
AU709831B2 (en) *	1995-11-13	1999-09-09	Takara Bio Inc.	Method for gene transfer into target cells with retrovirus
DE19605279A1 (de)	1996-02-13	1997-08-14	Hoechst Ag	Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
WO1997038723A1 (en) *	1996-04-16	1997-10-23	Immusol Incorporated	Targeted viral vectors
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US20060002949A1 (en)	1996-11-14	2006-01-05	Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc.	Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en)	1996-11-14	2004-09-28	The United States Of America As Represented By The Secretary Of The Army	Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
DE19649645A1 (de) *	1996-11-29	1998-06-04	Hoechst Ag	Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
US6432699B1 (en)	1997-03-28	2002-08-13	New York University	Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
WO1998047916A1 (en) *	1997-04-18	1998-10-29	President And Fellows Of Harvard College	Bifunctional polypeptides for cell-specific viral targeting
US6004798A (en) *	1997-05-14	1999-12-21	University Of Southern California	Retroviral envelopes having modified hypervariable polyproline regions
CA2318981A1 (en) *	1998-02-09	1999-08-12	Genzyme Corporation	Nucleic acid delivery vehicles
US6287857B1 (en)	1998-02-09	2001-09-11	Genzyme Corporation	Nucleic acid delivery vehicles
US7078483B2 (en) *	1998-04-29	2006-07-18	University Of Southern California	Retroviral vectors including modified envelope escort proteins
US20060292121A1 (en) *	1998-04-29	2006-12-28	Hall Frederick L	Retroviral vectors including modified envelope escort protein
AU4070499A (en)	1998-04-30	1999-11-16	Cornell Research Foundation Inc.	Adenoviral vectors with tandem fiber proteins
US6060316A (en) *	1998-06-09	2000-05-09	President And Fellows Of Harvard College	Methods of targeting of viral entry
AU767975B2 (en)	1998-09-11	2003-11-27	Genvec, Inc.	Alternatively targeted adenovirus
AUPQ425699A0 (en)	1999-11-25	1999-12-23	University Of Newcastle Research Associates Limited, The	A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
EP1301612A2 (de) *	2000-05-31	2003-04-16	Genvec, Inc.	Verfahren und zusammenfassung zur zielrichtung von adenoviralen vektoren
EP1372708B1 (de)	2001-02-13	2008-06-18	GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY	Impstoffe zur transkutanen immunisierung gegen reisediarrhö
AU2002953436A0 (en)	2002-12-18	2003-01-09	The University Of Newcastle Research Associates Limited	A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US11266736B2 (en)	2008-04-17	2022-03-08	Vin De Bona Trading Company Pte Ltd	Method of painting micro vesicles
WO2009127537A1 (en)	2008-04-17	2009-10-22	GÜNZBURG, Walter	Post release modification of viral envelopes
CN110418650A (zh)	2016-11-16	2019-11-05	免疫治疗有限公司	用于治疗过敏的核酸
EP3612556B8 (de)	2017-04-22	2024-11-20	Immunomic Therapeutics, Inc.	Verbesserte lamp konstrukte
WO2018204534A1 (en)	2017-05-02	2018-11-08	Immunomic Therapeutics, Inc.	Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JP2021523185A (ja)	2018-05-15	2021-09-02	イミュノミックセラピューティックス，インコーポレイテッドＩｍｍｕｎｏｍｉｃＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	アレルゲンを含む改善されたｌａｍｐ構築物
KR20220083773A (ko)	2019-10-18	2022-06-20	이뮤노믹 쎄라퓨틱스, 인크.	암 항원을 포함하는 개선된 lamp 구축물
CA3247515A1 (en)	2022-04-10	2023-10-19	Immunomic Therapeutics, Inc.	Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4364934A (en) *	1979-12-04	1982-12-21	Ortho Pharmaceutical Corporation	Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US5428132A (en) *	1987-10-11	1995-06-27	United States Of America	Conjugate and method for integration of foreign DNA into cells
DE68927996T2 (de) *	1988-02-05	1997-12-04	Hughes Howard Med Inst	Modifizierte hepatozyten und deren anwendung
WO1990012087A1 (en) *	1989-04-05	1990-10-18	Novacell Corporation	Infectious targetted replication-defective virion
FR2649119A1 (fr) *	1989-06-30	1991-01-04	Centre Nat Rech Scient	Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
EP1001032A3 (de) *	1989-08-18	2005-02-23	Chiron Corporation	Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
WO1991004753A1 (en) *	1989-10-02	1991-04-18	Cetus Corporation	Conjugates of antisense oligonucleotides and therapeutic uses thereof
AU660629B2 (en) *	1990-10-01	1995-07-06	University Of Connecticut, The	Targeting viruses and cells for selective internalization by cells
SE503225C2 (sv) *	1991-10-30	1996-04-22	Leif Lindholm Konsult Ab	Virus-antikroppskomplex för införing av virus i mammalieceller

1991
- 1991-10-30 SE SE9103183A patent/SE503225C2/sv not_active IP Right Cessation
1992
- 1992-10-28 CA CA002122613A patent/CA2122613C/en not_active Expired - Fee Related
- 1992-10-28 EP EP92922980A patent/EP0614486B1/de not_active Revoked
- 1992-10-28 DE DE69232782T patent/DE69232782T2/de not_active Revoked
- 1992-10-28 US US08/232,028 patent/US5695991A/en not_active Expired - Fee Related
- 1992-10-28 ES ES92922980T patent/ES2180538T3/es not_active Expired - Lifetime
- 1992-10-28 JP JP5508351A patent/JPH07502026A/ja not_active Ceased
- 1992-10-28 AT AT92922980T patent/ATE224442T1/de not_active IP Right Cessation
- 1992-10-28 WO PCT/SE1992/000745 patent/WO1993009221A1/en not_active Ceased

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7820157B2 (en)	1997-04-10	2010-10-26	University Of Southern California	Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
US8148509B2 (en)	1997-04-10	2012-04-03	University Of Southern California	Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
US8530441B2 (en)	1997-04-10	2013-09-10	University Of Southern California	Transgene delivering retrovirus targeting collagen exposed at site of tissue injury

Also Published As

Publication number	Publication date
ES2180538T3 (es)	2003-02-16
SE9103183D0 (sv)	1991-10-30
SE9103183L (sv)	1993-05-01
CA2122613C (en)	2003-08-19
EP0614486B1 (de)	2002-09-18
EP0614486A1 (de)	1994-09-14
ATE224442T1 (de)	2002-10-15
WO1993009221A1 (en)	1993-05-13
US5695991A (en)	1997-12-09
JPH07502026A (ja)	1995-03-02
CA2122613A1 (en)	1993-05-13
DE69232782T2 (de)	2003-02-20
DE69232782D1 (de)	2002-10-24

Legal Events

Date	Code	Title	Description
2004-06-01	NUG	Patent has lapsed

Publication	Publication Date	Title
US5695991A (en)	1997-12-09	Targeted delivery of virus vector to mammalian cells
FI110613B (fi)	2003-02-28	Kapsidia muodostava ja kysteiini-modifioitu kimeerinen MS2-vaippaproteiini
US6555367B1 (en)	2003-04-29	Complex of biotinylated viral vector and ligand for targeted gene delivery
US6274322B1 (en)	2001-08-14	Composition for introducing nucleic acid complexes into higher eucaryotic cells
Delpeyroux et al.	1986	A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles
Strand et al.	1976	Structural proteins of ribonucleic acid tumor viruses. Purification of envelope, core, and internal components.
Lee et al.	1998	The nucleolin binding activity of hepatitis delta antigen is associated with nucleolus targeting
US5166050A (en)	1992-11-24	Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
JP2528815B2 (ja)	1996-08-28	多効果免疫性蛋白質
JP2005511047A (ja)	2005-04-28	潜伏期膜タンパク質に対する抗体およびそれらの使用
Singh et al.	2015	Expression of rabies glycoprotein and ricin toxin B chain (RGP–RTB) fusion protein in tomato hairy roots: a step towards oral vaccination for rabies
JPH06506583A (ja)	1994-07-28	ベクターとして修正された植物ウイルス
BE1000811A4 (fr)	1989-04-11	Anticorps monoclonaux, peptides et compositions les contenant, destinees au diagnostic et au traitement des infections par le virus hiv.
JPH04501708A (ja)	1992-03-26	細胞膜ブレンディング剤を含む分子共役体
WO1983002393A1 (en)	1983-07-21	Viruses with recombinant surface proteins
CA2224907A1 (en)	1997-02-13	Methods and means for targeted gene delivery
SK160391A3 (en)	1995-07-11	Recombinant proteine joining complex viral antigen hiv-1
JPS63501125A (ja)	1988-04-28	ヒトレトロウイルス遺伝子を発現する組換えワクチニアウイルス
CN105949316A (zh)	2016-09-21	抗EGFRvIII嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN102690842B (zh)	2014-04-23	一种表达人抗体全基因的重组腺病毒(rAdv)载体及其方法
US5364761A (en)	1994-11-15	Method for isolating a DNA encoding an autonomously replicating sequence
JPH02142737A (ja)	1990-05-31	擬似狂犬病ウイルスワクチン
CN120518757B (zh)	2025-09-23	一种聚乙二醇化多价抗西尼罗病毒单链抗体
US20060018900A1 (en)	2006-01-26	Self antigen vaccines for treating B-cell lymphomas and other cancers
Teramoto et al.	1980	Detection of novel murine mammary tumor viruses by interspecies immunoassays